Clinical Significance Of Plasma HSP90? Level For Patients With Non-small-cell Lung Cancer Undergoing Chemotherapy

Background: In recent years,with the development of industrialization and the aggravation of air pollution,the incidence of cancer is increasing,which has aroused people's wide concern.AS global cancer statistics reports,there will be an estimated 18.1million new cancer cases and 9.6 million cancer deaths in 2018.The incidence and mortality of lung cancer are higher.there will be an estimated 2.1 million new lung cancer cases and 1.8 million lung cancer deaths in 2018,It accounts for one-fifth of all cancer deaths.The reason why the incidence and mortality of lung cancer are so high is that there are often no obvious clinical symptoms and signs in the early stage of lung cancer,which is easily ignored by patients.When most patients go to the doctor due to clinical symptoms,they are already in the late stage and the survival rate is very low.Lung cancer is a malignant tumor originated from the bronchial mucosa or glands.According to the histopathological classification,it can be divided into non-small cell lung cancer and small cell lung cancer.Non-small cell lung cancer includes squamous cell cancer,adenocarcinoma and large cell lung cancer,accounting for about 85% of all lung cancer.Due to the differences in the pathological types of lung cancer,the choice of treatment options is also different.Small cell lung cancer is prone to metastasis,so surgical treatment cannot achieve good results.For early(stage I,II)NSCLC,surgical treatment can achieve better results.Due to the loss of surgical opportunities in advanced non-small cell lung cancer,most patients are treated with comprehensive chemotherapy,and some patients can obtain certain curative effect at the initial stage of treatment.However,the 5-year survival rate of patients is about 16%,due to the occurrence of drug resistance in the later stage.Therefore,the early diagnosis andtreatment of lung cancer are particularly important.Nowadays,there are various diagnostic methods for lung cancer,including: imaging examination,fiberoptic bronchoscopy,serum tumor markers,molecular biomarkers,exhaled air markers,etc.Serum tumor markers are popular among them because of its rapid,simple and non-invasive.Heat shock protein(HSP)is a kind of protein produced by the body in response to stress.It is mainly used as a molecular chaperone to participate in protein synthesis,folding,maintain protein conformation and protect cells from damage.Heat shock protein(HSP)can be divided into HSP110,HSP90,HSP70 and HSP60 families according to their molecular weight.Heat shock protein 90?(HSP90?),as a member of HSP90 family,plays an important role in maintaining molecular chaperone structure,regulating cell cycle and apoptosis,and coordinating hormone signaling.Heat shock protein 90?(HSP90?)is a novel tumor marker during the progression of lung cancer.At present,heat shock protein 90?(HSP90?)has been confirmed to be increased in non-small cell lung cancer,gastric cancer,pancreatic cancer,brain glioma,meningioma and other tumor cells,but there are still few studies on the evaluation of heat shock protein 90?(HSP90?)in the efficacy of chemotherapy for lung cancer at home and abroad.The purpose of this study was to evaluate the effect of plasma heat shock protein90? on chemotherapy for non-small cell lung cancer(NSCLC).Objective: To investigate the dynamic change and the clinical significance of plasma heat shock protein 90?(HSP90?)in patients with non-small-cell lung cancer(NSCLC)before and after chemotherapy.Methods: Plasma HSP90? level of 47 individuals with NSCLC before and after chemotherapy was detected by ELISA assay.The efficacy of chemotherapy,the pathological classification and the hydrothorax were also analyzed.Results: Plasma level of HSP90? was significantly lowered after the 4th cycle ofchemotherapy(P<0.05).Plasma HSP90? level in patients with effective response was significantly lower after the 4th cycle of chemotherapy(P<0.05).No significant difference of plasma HSP90? level was observed between lung squamous carcinoma and lung adenocarcinoma had no significant difference(P<0.05).Plasma level of HSP90?was significantly lower after the 4th cycle of chemotherapy in patients with hydrothorax(P<0.05).Conclusion: Detection of the change of plasma HSP90? level in patients with NSCLC before and after chemotherapy is useful in evaluating the effect of chemotherapy and formulating the later therapeutic schedule.